ALZN Alzamend Neuro, Inc.
Healthcare$1.15+1.77%ClosedMarket Cap: $3.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.97
P/S
0.00
EV/EBITDA
-0.12
DCF Value
$7.42
FCF Yield
-173.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-177.5%
ROA
-174.2%
ROIC
-322.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 null | $0.00 | NaN% | $-2.2M | $-2.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-998.1K | $-1.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-2.7M | $-2.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-1.1M | $-1.1M | $— | — |
| FY null | $0.00 | NaN% | $-4.5M | $-4.5M | $— | — |
| Q3 null | $0.00 | NaN% | $-1.0M | $-1.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.4M | $-1.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-962.4K | $-974.4K | $— | — |
| Q4 null | $0.00 | NaN% | $-850.1K | $-851.5K | $— | — |
| FY null | $0.00 | NaN% | $-9.9M | $-9.9M | $— | — |
| Q3 2024 | $0.00 | -Infinity% | $-2.7M | $-2.7M | $-33.97 | — |
| Q2 2024 | $0.00 | -Infinity% | $-2.9M | $-2.9M | $-39.85 | — |